Analysts Set Ophthotech Corp (OPHT) PT at $13.00

Shares of Ophthotech Corp (NASDAQ:OPHT) have received an average rating of “Hold” from the thirteen ratings firms that are covering the firm. Thirteen investment analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $13.00.

Separately, Zacks Investment Research cut shares of Ophthotech Corp from a “buy” rating to a “hold” rating in a research report on Monday, February 20th.

ILLEGAL ACTIVITY WARNING: “Analysts Set Ophthotech Corp (OPHT) PT at $13.00” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://sportsperspectives.com/2017/04/21/analysts-set-ophthotech-corp-opht-pt-at-13-00.html.

Shares of Ophthotech Corp (NASDAQ:OPHT) traded down 1.44% during midday trading on Tuesday, reaching $2.74. The company’s stock had a trading volume of 492,480 shares. The company has a 50 day moving average price of $3.39 and a 200-day moving average price of $15.74. The stock’s market capitalization is $98.11 million. Ophthotech Corp has a 52 week low of $2.71 and a 52 week high of $65.96.

In other news, CFO Glenn Sblendorio sold 7,388 shares of Ophthotech Corp stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $3.56, for a total transaction of $26,301.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. M&T Bank Corp boosted its stake in Ophthotech Corp by 2.4% in the third quarter. M&T Bank Corp now owns 9,591 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 226 shares during the period. California State Teachers Retirement System boosted its stake in Ophthotech Corp by 0.8% in the third quarter. California State Teachers Retirement System now owns 64,552 shares of the biopharmaceutical company’s stock valued at $2,978,000 after buying an additional 500 shares during the period. Swiss National Bank boosted its stake in Ophthotech Corp by 1.3% in the third quarter. Swiss National Bank now owns 42,622 shares of the biopharmaceutical company’s stock valued at $1,966,000 after buying an additional 534 shares during the period. Teachers Advisors LLC boosted its stake in Ophthotech Corp by 1.2% in the third quarter. Teachers Advisors LLC now owns 49,244 shares of the biopharmaceutical company’s stock valued at $2,272,000 after buying an additional 573 shares during the period. Finally, BlackRock Investment Management LLC boosted its stake in Ophthotech Corp by 0.9% in the third quarter. BlackRock Investment Management LLC now owns 114,778 shares of the biopharmaceutical company’s stock valued at $5,295,000 after buying an additional 1,003 shares during the period. 95.66% of the stock is owned by institutional investors and hedge funds.

Ophthotech Corp Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

5 Day Chart for NASDAQ:OPHT

Receive News & Ratings for Ophthotech Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply